Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | PLAT | P00750 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LGMN | Q99538 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5789042 | 1.00 | PLG (0.53) | PLGPLATLMNAMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL11075182 | 0.98 | PLG (0.52) | PLGPLATLMNAMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL1068668 | 0.98 | PLG (0.52) | PLGPLATLMNAMAPTMEN1 | |
| SCHEMBL15308689 | 0.89 | PLG (0.46) | PLGPLATLMNAMAPTMEN1 | |
| SCHEMBL4700703 | 0.87 | PLG (0.44) | PLGPLATLMNAMAPTMEN1 | |
| SCHEMBL4700700 | 0.87 | PLG (0.44) | PLGPLATLMNAMAPTMEN1 | |
| SCHEMBL2375356 | 0.85 | MAPT (0.60) | MAPTMEN1KMT2AALDH1A1PPM1B | |
| SCHEMBL4221 | 0.85 | — | — | |
| SCHEMBL8891623 | 0.85 | MAPT (0.60) | MAPTMEN1KMT2AALDH1A1PPM1B | |
| SCHEMBL237380 | 0.85 | MAPT (0.60) | MAPTMEN1KMT2AALDH1A1PPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| EP-4003959-A1 | TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | Bayer AS (NO) | 2022-06-01 | — | — | EP | disclosed |
| CN-106456602-B | Substituted indole MCL-1 inhibitors | 范德比尔特大学 | 2020-11-24 | — | — | CN | disclosed |
| US-8987256-B2 | Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| EP-2828257-A1 | ANTIBACTERIAL COMPOUNDS | Biota Europe Ltd (GB) | 2015-01-28 | — | — | EP | disclosed |
| WO-2013177349-A2 | QUINAZOLINEDIONES AS TANKYRASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013138860-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LIMITED (GB) | 2013-09-26 | — | — | WO | disclosed |
| EP-2625178-A1 | BACTERIA TOPOISOMERASE II INHIBITING 2-ETHYLCARBAMOYLAMINO-1, 3-BENZOTHIAZOL-5-YLS | Biota Europe Ltd (GB) | 2013-08-14 | — | — | EP | disclosed |
| EP-2268625-B1 | OXO-HETEROCYCLIC SUBSTITUTED CARBOXYLIC ACID DERIVATES AND THE USE THEREOF | Bayer Pharma AG (DE) | 2012-05-16 | — | — | EP | disclosed |
| EP-0353474-A2 | Glycerin derivative and its pharmacological use | Eisai Co., Ltd. (JP) | 1990-02-07 | — | — | EP | disclosed |
| CN-1039414-A | Glycerol derivatives and pharmaceutical use thereof | EISAI CO LTD (JP) | 1990-02-07 | — | — | CN | disclosed |
| US-4621088-A | N-acyl derivatives of amino acids and their esters, and drugs in which they are present | PANMEDICA (FR) | 1986-11-04 | — | — | US | disclosed |
| US-4578404-A | Pharmaceutical composition for treating nephritis and method for treating nephritis | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1986-03-25 | — | — | US | disclosed |
| EP-0055145-B1 | 4-(AMINOMETHYL)CYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1984-12-05 | — | — | EP | disclosed |
| EP-0041827-B1 | A N-(BENZYLIDENE) AMINOMETHYL-CYCLOHEXANE-CARBOXYLIC ACID | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1984-03-21 | — | — | EP | disclosed |
| US-4387102-A | 4-(N-(3',4'-Methylenedioxybenzylidene)-aminomethyl)cyclohexane-1-carboxylic acid and derivatives thereof and pharmaceutical composition thereof | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1983-06-07 | — | — | US | disclosed |
| US-4382955-A | ANTIINFLAMMATORY, ANTICOAGULANTS | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1983-05-10 | — | — | US | disclosed |
| EP-0055145-A1 | 4-(Aminomethyl)cyclohexane-1-carboxylic acid derivatives | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1982-06-30 | — | — | EP | disclosed |
| EP-0041827-A2 | A N-(benzylidene) aminomethyl-cyclohexane-carboxylic acid | KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1981-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039309-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL3 | PLG 4681/4885PLAT 4690/4885LMNA 3060/4885 |
| US-12195472-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL3 | PLG 4681/4885PLAT 4690/4885LMNA 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.